Compare Stocks → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALTNASDAQ:CARANASDAQ:COGTNASDAQ:JANX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$7.20+1.7%$9.35$2.09▼$14.84$510.41M0.055.35 million shs2.31 million shsCARACara Therapeutics$0.70+4.2%$0.83$0.50▼$4.67$38.27M0.7643,507 shs306,131 shsCOGTCogent Biosciences$6.01-8.1%$7.00$3.67▼$13.50$574.62M1.52.02 million shs1.21 million shsJANXJanux Therapeutics$47.10-2.3%$37.62$5.65▼$58.69$2.43B4.18753,435 shs544,664 shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-6.47%+0.57%-17.00%-23.71%+35.37%CARACara Therapeutics-5.02%-8.24%-18.09%+18.95%-82.91%COGTCogent Biosciences-6.03%+0.15%+13.15%+47.63%-39.11%JANXJanux Therapeutics-3.15%+0.52%+25.12%+401.14%+225.74%Mysterious Gold Leverage Just Announced (Ad)World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune1.3496 of 5 stars3.31.00.00.03.21.70.0CARACara Therapeutics3.7972 of 5 stars3.41.00.04.21.81.71.3COGTCogent Biosciences1.5675 of 5 stars4.41.00.00.01.30.00.6JANXJanux Therapeutics3.6909 of 5 stars4.54.00.00.02.63.30.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune2.67Moderate Buy$15.00108.33% UpsideCARACara Therapeutics2.75Moderate Buy$9.751,292.86% UpsideCOGTCogent Biosciences2.71Moderate Buy$13.67127.40% UpsideJANXJanux Therapeutics3.00Buy$61.3330.22% UpsideCurrent Analyst RatingsLatest CARA, ALT, JANX, and COGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024JANXJanux TherapeuticsJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.004/10/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/1/2024ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.003/28/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/28/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/21/2024JANXJanux TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$62.003/20/2024JANXJanux TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$100.003/13/2024JANXJanux TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$24.00 ➝ $48.003/11/2024JANXJanux TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$53.003/6/2024CARACara TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/5/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$430K1,187.00N/AN/A$2.75 per share2.62CARACara Therapeutics$20.97M1.82N/AN/A$1.05 per share0.67COGTCogent BiosciencesN/AN/AN/AN/A$2.30 per shareN/AJANXJanux Therapeutics$8.08M301.14N/AN/A$7.46 per share6.31Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.45M-$1.65N/AN/AN/A-20,780.75%-44.77%-40.72%5/9/2024 (Estimated)CARACara Therapeutics-$118.51M-$2.18N/AN/AN/A-565.21%-122.10%-89.64%5/20/2024 (Estimated)COGTCogent Biosciences-$192.41M-$2.40N/AN/AN/AN/A-86.67%-58.11%5/14/2024 (Estimated)JANXJanux Therapeutics-$58.29M-$1.34N/AN/AN/A-721.18%-17.88%-15.95%5/14/2024 (Estimated)Latest CARA, ALT, JANX, and COGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023ALTAltimmune-$0.35-$0.33+$0.02-$0.12N/A$0.04 million3/8/2024Q4 2023JANXJanux Therapeutics-$0.37-$0.25+$0.12-$0.25$0.98 million$2.46 million3/4/202412/31/2023CARACara Therapeutics-$0.57-$0.59-$0.02-$0.59$2.34 million$3.00 million 2/26/202412/31/2023COGTCogent Biosciences-$0.55-$0.63-$0.08-$0.63N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A17.2617.26CARACara TherapeuticsN/A4.544.43COGTCogent BiosciencesN/A7.097.09JANXJanux TherapeuticsN/A26.8026.80OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%CARACara Therapeutics44.66%COGTCogent BiosciencesN/AJANXJanux Therapeutics75.39%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%CARACara Therapeutics4.20%COGTCogent Biosciences5.10%JANXJanux Therapeutics35.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5970.89 million67.99 millionOptionableCARACara Therapeutics5554.67 million52.36 millionOptionableCOGTCogent Biosciences16495.61 million90.74 millionOptionableJANXJanux Therapeutics6451.66 million33.37 millionOptionableCARA, ALT, JANX, and COGT HeadlinesSourceHeadlineCerity Partners LLC Makes New $654,000 Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)marketbeat.com - April 24 at 4:43 AMJanux Therapeutics (NASDAQ:JANX) Shares Down 4.1% marketbeat.com - April 17 at 2:37 PMTake the Money and Run: 3 Overbought Stocks to Sell ASAPinvestorplace.com - April 17 at 1:12 PMValidea Detailed Fundamental Analysis - JANXnasdaq.com - April 17 at 7:35 AMJanux Therapeutics (NASDAQ:JANX) Now Covered by Analysts at Jonestradingamericanbankingnews.com - April 17 at 3:48 AMJonesTrading Initiates Coverage of Janux Therapeutics (JANX) with Buy Recommendationmsn.com - April 16 at 11:00 PMJanux a new buy at Jones on lead assets for solid tumorsmsn.com - April 16 at 6:00 PMThese 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?investorplace.com - April 16 at 1:19 PMA Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 Analystsbenzinga.com - April 16 at 1:00 PMJanux (JANX) Rises Almost 50% in a Week on Buyout Rumorszacks.com - April 15 at 1:55 PMJanux Therapeutics (NASDAQ:JANX) Shares Gap Down to $52.65marketbeat.com - April 15 at 12:53 PMJanux Therapeutics, Inc. (NASDAQ:JANX) Given Average Recommendation of "Buy" by Brokeragesamericanbankingnews.com - April 15 at 4:10 AMJanux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainablezacks.com - April 12 at 9:50 AMWhy Janux Therapeutics Stock Is Crushing It This Weekfool.com - April 12 at 5:40 AMStocks See Continued Pressure as Bond Yields Climbtheglobeandmail.com - April 11 at 12:58 PMWhy Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?benzinga.com - April 11 at 12:58 PMBiotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Optionsfinance.yahoo.com - April 11 at 12:58 PMWall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a Betzacks.com - April 11 at 10:55 AMBiotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Optionsinvestors.com - April 11 at 9:17 AMWhy Janux Therapeutics Stock Soared as the Market Sagged Todayfool.com - April 10 at 6:39 PMJanux Therapeutics (NASDAQ:JANX) Sees Unusually-High Trading Volumemarketbeat.com - April 10 at 3:46 PMJanux Therapeutics surges amid report of takeover interestmsn.com - April 10 at 3:45 PMJanux Therapeutics (NASDAQ:JANX) Stock Price Up 6.9%marketbeat.com - April 8 at 1:45 PMAfter Plunging -11.78% in 4 Weeks, Here's Why the Trend Might Reverse for Janux Therapeutics (JANX)zacks.com - April 8 at 10:35 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHigher Oil Prices Could Give NextEra’s Stock Earnings a BoostApril 24, 2024 10:40 AMView Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost3M Spun Off Its Health Division, Is It Still A Buy?April 4, 2024 7:47 AMView 3M Spun Off Its Health Division, Is It Still A Buy?4 Dividend Aristocrats Trading at a DiscountApril 1, 2024 6:10 AMView 4 Dividend Aristocrats Trading at a DiscountCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? April 9, 2024 6:07 AMView Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? Undervalued UnitedHealth Group Won’t Be For LongApril 16, 2024 10:53 AMView Undervalued UnitedHealth Group Won’t Be For LongAll Headlines Company DescriptionsAltimmuneNASDAQ:ALTAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Cara TherapeuticsNASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Cogent BiosciencesNASDAQ:COGTCogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Janux TherapeuticsNASDAQ:JANXJanux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.